🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Truist reiterates Hold on Aveanna Healthcare shares, boosts 2024-2025 EBITDA projections

EditorAhmed Abdulazez Abdulkadir
Published 09/09/2024, 13:16
AVAH
-


On Monday, Truist Securities maintained a Hold rating on shares of Aveanna Healthcare Holdings Inc (NASDAQ: AVAH) and reinstated a price target of $6.00. The decision follows an adjustment of the firm's earnings estimates for the healthcare provider for the years 2024 and 2025.


The firm's analyst has raised the expected adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for Aveanna Healthcare for the year 2024 to $160 million, up from the previous estimate of $152 million. Similarly, the estimate for the year 2025 has been increased to $171 million from the earlier forecast of $165 million.


The price target reinstatement is based on a valuation of approximately 15.3 times the company's projected adjusted EBITDA for the year 2025. The analyst's commentary highlighted the revised EBITDA estimates as the basis for maintaining the current stock rating and price target.


Aveanna Healthcare Holdings Inc., which is listed on the NASDAQ, specializes in providing home care services. The company's stock performance and financial outlook are closely monitored by investors and analysts alike.


In other recent news, Aveanna Healthcare Holdings Inc. reported significant improvements in its financial performance. The company's second-quarter earnings for 2024 indicated a 7% increase in revenue, amounting to approximately $505 million, and a notable 27.3% rise in adjusted EBITDA, reaching $45.6 million. These positive outcomes were attributed to strategic initiatives, including partnerships with government and preferred payers, leading to double-digit rate improvements in states like Georgia and Massachusetts.


JPMorgan (NYSE:JPM) maintained its underweight rating on Aveanna Healthcare but revised its revenue forecast for 2024 to $1.987 billion, a 4.8% year-over-year increase from the previous estimate of $1.970 billion. Adjusted EBITDA expectations were also raised to $159 million, reflecting a 14.5% year-over-year growth from the former estimate of $147 million.


RBC Capital raised its price target for Aveanna Healthcare to $5, up from $3, due to strong execution on state legislative initiatives and securing preferred payor arrangements. The company expects full-year 2024 revenue to surpass $1.97 billion and adjusted EBITDA to exceed $150 million.


Despite labor market challenges, Aveanna Healthcare has made strides in improving caregiver hiring and retention. The company also plans to enhance reimbursement rates and value-based agreements, particularly in states like Georgia, Massachusetts, and California. These recent developments reflect Aveanna Healthcare's strategic moves and operational progress, which have been recognized by analyst firms such as RBC Capital and JPMorgan.


InvestingPro Insights


In light of the recent analysis by Truist Securities on Aveanna Healthcare Holdings Inc (NASDAQ: AVAH), let's consider some additional insights provided by InvestingPro. The company's market capitalization stands at $1.05 billion, reflecting its scale in the home care services market. Despite the positive EBITDA adjustments for 2024 and 2025 by Truist Securities, InvestingPro data indicates that Aveanna Healthcare is not expected to be profitable this year, with a negative P/E ratio of -8.43. This aligns with the analyst's anticipation that profitability may not be on the immediate horizon.


However, investors may find some solace in the company's stock performance, which has shown a strong return over the past month, three months, and six months, with a particularly impressive one-year price total return of 289.93%. This volatility and growth potential are underscored by an InvestingPro Tip noting a high return over the last year and a large price uptick over the past six months. Another key point to consider is that Aveanna does not pay a dividend, which might be relevant for income-focused investors.


For those seeking a deeper dive into Aveanna Healthcare's financials and stock performance, InvestingPro offers additional tips that can provide a more comprehensive understanding of the company's potential. For further information and insights, visit https://www.investing.com/pro/AVAH, where a total of 7 InvestingPro Tips are available to guide your investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.